[Federal Register Volume 66, Number 226 (Friday, November 23, 2001)]
[Notices]
[Pages 58742-58743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-29210]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS-3079-N]


Medicare Program; Meeting of the Diagnostic Imaging Panel of the 
Medicare Coverage Advisory Committee--January 10, 2002

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: This notice announces a public meeting of the Diagnostic 
Imaging Panel (the Panel) of the Medicare Coverage Advisory Committee 
(the Committee). The Panel provides advice and recommendations to the 
Committee about clinical issues. The Panel will hear and discuss 
presentations from interested persons regarding whether and when it is 
scientifically justified to use FDG Positron Emission Tomography (PET) 
or other neuroimaging devices for the diagnosis and patient management 
of those with Alzheimer's disease (AD). The focus is on the marginal 
contribution of FDG-PET in various common clinical scenarios to patient 
outcomes. The following three scenarios will be evaluated:
     Asymptomatic patients who are at high risk of AD due to 
positive family history.
     Patients with mild cognitive impairment or similar 
syndrome.
     Patients with dementia.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. App. 2, section 10(a)(1) and (a)(2)).

DATES: The Meeting: January 10, 2002 from 8 a.m. until 4:30 p.m., 
E.D.T.
    Deadline for Presentations and Comments: December 27, 2001, 5 p.m., 
E.D.T.
    Special Accommodations: Persons attending the meeting who are 
hearing or visually impaired, or have a condition that requires special 
assistance or accommodations, are asked to notify the Executive 
Secretary by December 20, 2001 (see FOR FURTHER INFORMATION CONTACT).

ADDRESSES: The Meeting: The meeting will be held at the Baltimore 
Convention Center, Room 327-328, One West Pratt Street, Baltimore, MD 
21201.
    Presentations and Comments: Submit formal presentations and written 
comments to Janet A. Anderson, Executive Secretary; Office of Clinical 
Standards and Quality; Centers for Medicare & Medicaid Services; 7500 
Security Boulevard; Mail Stop C1-09-06; Baltimore, MD 21244.
    Web site: You may access up-to-date information on this meeting at 
www.hcfa.gov/coverage.
    Hotline: You may access up-to-date information on this meeting on 
the CMS Advisory Committee Information Hotline, 1-877-449-5659 (toll 
free) or in the Baltimore area (410) 786-9379.

FOR FURTHER INFORMATION CONTACT: Janet A. Anderson, Executive 
Secretary, 410-786-2700.

SUPPLEMENTARY INFORMATION: On August 13, 1999, we published a notice in 
the Federal Register (64 FR 44231) to describe the Medicare Coverage 
Advisory Committee (the Committee), which provides advice and 
recommendations to us about clinical issues. This notice announces the 
following public meeting of the Diagnostic Imaging Panel (the Panel) of 
the Committee.

Current Panel Members:

    Frank Papatheofanis, M.D., Ph.D.; Barbara McNeil, M.D., Ph.D.; 
Carole Flamm, M.D., M.P.H.; Jeffrey Lerner, Ph.D.; Michael Manyak, 
M.D.; Donna Novak, B.A.; Manuel Cerqueira, M.D.; Kim Burchiel, M.D.; 
Steven Guyton, M.D.; Sally Hart, J.D.; and Michael Klein, M.B.A.

Meeting Topic:

    The Panel will hear and discuss presentations from interested 
persons regarding FDG Positron Emission Tomography (PET) imaging for 
Alzheimer's disease (AD), mild cognitive impairment, and dementia.

Procedure and Agenda:

    This meeting is open to the public. The Panel will hear oral 
presentations from the public for approximately 90 minutes. The Panel 
may limit the number and duration of oral presentations to the time 
available. If you wish to make formal presentations, you must notify 
the Executive Secretary named in the FOR FURTHER INFORMATION CONTACT 
section, and submit the following by the Deadline for Presentations and 
Comments date listed in the DATES section of this notice: a brief 
statement of the general nature of the evidence or arguments you wish 
to present, and the names and addresses of proposed participants. A 
written copy of your presentation must be provided to each Panel member 
before offering your public comments. We will request that you declare 
at the meeting whether or not you have any financial involvement with 
manufacturers of any items or

[[Page 58743]]

services being discussed (or with their competitors).
    After the public and CMS presentations, the Panel will deliberate 
openly on the topic. Interested persons may observe the deliberations, 
but the Panel will not hear further comments during this time except at 
the request of the chairperson. The Panel will also allow approximately 
a 30-minute open public session for any attendee to address issues 
specific to the topic. At the conclusion of the day, the members will 
vote and the Panel will make its recommendation.

    Authority: 5 U.S.C. App. 2, section 10(a)(1) and (a)(2).

(Catalog of Federal Domestic Assistance Program No. 93.774, 
Medicare--Supplementary Medical Insurance Program)


    Dated: November 14, 2001.
Jeffrey L. Kang,
Director, Office of Clinical Standards and Quality, Centers for 
Medicare & Medicaid Services.
[FR Doc. 01-29210 Filed 11-21-01; 8:45 am]
BILLING CODE 4120-01-P